JP Morgan Maintains Neutral on Molecular Partners, Lowers Price Target to $3.75

Benzinga · 1d ago
JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lowers the price target from $4 to $3.75.